Associations - IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)

IDH2 mutation	Acute Myelogenous Leukemia	IDH2 mutation	Acute Myelogenous Leukemia	enasidenib Sensitive: A1 - Approval enasidenib Sensitive : A1	enasidenib Sensitive: A1 - Approval enasidenib Sensitive : A1
IDH2 mutation	Oligodendroglioma	IDH2 mutation	Oligodendroglioma	vorasidenib Sensitive: A1 - Approval vorasidenib Sensitive : A1	vorasidenib Sensitive: A1 - Approval vorasidenib Sensitive : A1
IDH2 mutation	Astrocytoma	IDH2 mutation	Astrocytoma	vorasidenib Sensitive: A1 - Approval vorasidenib Sensitive : A1	vorasidenib Sensitive: A1 - Approval vorasidenib Sensitive : A1
IDH2 mutation	Acute Myelogenous Leukemia	IDH2 mutation	Acute Myelogenous Leukemia	venetoclax Sensitive: A2 - Guideline venetoclax Sensitive : A2	venetoclax Sensitive: A2 - Guideline venetoclax Sensitive : A2
IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2
IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2
IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	carmustine Sensitive: A2 - Guideline carmustine Sensitive : A2	carmustine Sensitive: A2 - Guideline carmustine Sensitive : A2
IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	lomustine Sensitive: A2 - Guideline lomustine Sensitive : A2	lomustine Sensitive: A2 - Guideline lomustine Sensitive : A2
IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
IDH2 mutation	Astrocytoma	IDH2 mutation	Astrocytoma	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2
IDH2 mutation	Astrocytoma	IDH2 mutation	Astrocytoma	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2
IDH2 mutation	Astrocytoma	IDH2 mutation	Astrocytoma	etoposide IV Sensitive: A2 - Guideline etoposide IV Sensitive : A2	etoposide IV Sensitive: A2 - Guideline etoposide IV Sensitive : A2
IDH2 mutation	Astrocytoma	IDH2 mutation	Astrocytoma	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2
IDH2 mutation	Astrocytoma	IDH2 mutation	Astrocytoma	carmustine Sensitive: A2 - Guideline carmustine Sensitive : A2	carmustine Sensitive: A2 - Guideline carmustine Sensitive : A2
IDH2 mutation	Astrocytoma	IDH2 mutation	Astrocytoma	lomustine Sensitive: A2 - Guideline lomustine Sensitive : A2	lomustine Sensitive: A2 - Guideline lomustine Sensitive : A2
IDH2 mutation	Astrocytoma	IDH2 mutation	Astrocytoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
IDH2 mutation	Astrocytoma	IDH2 mutation	Astrocytoma	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2
IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2
IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2
IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	etoposide IV Sensitive: A2 - Guideline etoposide IV Sensitive : A2	etoposide IV Sensitive: A2 - Guideline etoposide IV Sensitive : A2
IDH2 mutation + BRAF V600E	Astrocytoma	IDH2 mutation + BRAF V600E	Astrocytoma	vemurafenib + cobimetinib Sensitive: A2 - Guideline vemurafenib + cobimetinib Sensitive : A2	vemurafenib + cobimetinib Sensitive: A2 - Guideline vemurafenib + cobimetinib Sensitive : A2
IDH2 mutation + BRAF V600E	Astrocytoma	IDH2 mutation + BRAF V600E	Astrocytoma	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2
IDH2 mutation + NTRK3 fusion	Astrocytoma	IDH2 mutation + NTRK3 fusion	Astrocytoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
IDH2 mutation + NTRK2 fusion	Astrocytoma	IDH2 mutation + NTRK2 fusion	Astrocytoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
IDH2 mutation + NTRK1 fusion	Astrocytoma	IDH2 mutation + NTRK1 fusion	Astrocytoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
IDH2 mutation + NTRK3 fusion	Astrocytoma	IDH2 mutation + NTRK3 fusion	Astrocytoma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
IDH2 mutation + NTRK2 fusion	Astrocytoma	IDH2 mutation + NTRK2 fusion	Astrocytoma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
IDH2 mutation + NTRK1 fusion	Astrocytoma	IDH2 mutation + NTRK1 fusion	Astrocytoma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
IDH2 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E	Oligodendroglioma	IDH2 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E	Oligodendroglioma	vemurafenib + cobimetinib Sensitive: A2 - Guideline vemurafenib + cobimetinib Sensitive : A2	vemurafenib + cobimetinib Sensitive: A2 - Guideline vemurafenib + cobimetinib Sensitive : A2
IDH2 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E	Oligodendroglioma	IDH2 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E	Oligodendroglioma	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2
IDH2 mutation + Chr del(1p) + Chr del(19q) + NTRK3 fusion	Oligodendroglioma	IDH2 mutation + Chr del(1p) + Chr del(19q) + NTRK3 fusion	Oligodendroglioma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
IDH2 mutation + Chr del(1p) + Chr del(19q) + NTRK2 fusion	Oligodendroglioma	IDH2 mutation + Chr del(1p) + Chr del(19q) + NTRK2 fusion	Oligodendroglioma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2

IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)

Associations(133)

Associations
(133)